AnaptysBio Inc (NAS:ANAB)
$ 24.75 -0.17 (-0.68%) Market Cap: 676.14 Mil Enterprise Value: 338.45 Mil PE Ratio: 0 PB Ratio: 14.14 GF Score: 60/100

AnaptysBio Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 09:20PM GMT
Release Date Price: $71.71 (-0.35%)
Unidentified Analyst

Thank you so much for attending the Bank of America Health Care Conference at Vegas. My name is Ching Wong, and I am an equity analyst from the large-cap biotech team. And today, it's my pleasure to host CEO of AnaptysBio, Hamza Suria. And in the next like maybe 20, 25 minutes, he will give us a presentation about the company and the program update, and we might have a few minutes for follow-up Q&As. Welcome.

Hamza Suria
AnaptysBio, Inc. - President, CEO & Director

Thank you, Ching, for the introduction and thank you to BAML for having us here. My name is Hamza Suria. I'm President and CEO of AnaptysBio. I'll be providing a brief update regarding our progress and upcoming milestones.

As shown on Slide 2, I will be making forward-looking statements during the course of my presentation. Please review our SEC filings for relevant risks and some additional considerations.

AnaptysBio is a clinical stage antibody development company. We're focused on first-in-class opportunities in the inflammatory diseases, and we have an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot